FDA Determines Regulatory Review Period for REMODULIN Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for REMODULIN, a human drug product, in accordance with the law. This decision was prompted by a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.